Andrea Wang-Gillam MD

Gastrointestinal Cancer, Hematologic Oncology

Associate Professor, Internal Medicine, Washington University School of Medicine

4921 Parkview Pl# DvSt. Louis, MO 63110
Phone+1 800-647-2098
Fax+1 314-362-3192

Dr. Wang-Gillam is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wang-Gillam's full profile Already have an account?

Education & Training

University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2002 - 2004
Cleveland Clinic FoundationInternship, Internal Medicine, 2001 - 2002
University of Arkansas For Medical Sciences College of MedicineClass of 2001

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MO State Medical License 2007 - 2027
AR State Medical License 2003 - 2009
OH State Medical License 2001 - 2003
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2013-2017
CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2013-2017
CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2013-2017

Clinical Trials

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Start of enrollment: 2011 May 10
ACTIVE_NOT_RECRUITING
PHASE1
Registry Study - Whipple at the Splenic Artery Start of enrollment: 2010 Sep 20
COMPLETED
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
COMPLETED
PHASE1

Publications & Presentations

PubMed

12 citations
Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.
Patrick M Grierson, Crystal Wolf, Rama Suresh, Andrea Wang-Gillam, Benjamin R Tan
Clinical Cancer Research. 2025-09-02
5 citations
Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR -1, -2, and -3, in Patients with Refractory Metastatic Colorectal Cancer.
Xiaofei Zhou, Xiaoyan Yang, Boris Grinshpun, Adekemi Taylor, Laura Strong
Journal of Clinical Pharmacology. 2025-07-01
58 citations
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients.
Xiuli Zhang, S Peter Goedegebuure, Michael Y Chen, Rashmi Mishra, Felicia Zhang
Genome Medicine. 2024-11-14

Journal Articles

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma
Andrea Wang-Gillam, Howard S Hochster, JAMA Oncology
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers
Haeseong Park, Andrea Wang-Gillam, Caron Rigden, Katrina S Pedersen, Nikolaos A Trikalinos, JAMA Oncology

Lectures

Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

FOLFIRINOX for the Treatment of Advanced Gastroesophageal CancersMay 2020

Press Mentions

Verastem Oncology Reports Second Quarter 2018 Financial ResultsAugust 8th, 2018
Verastem Oncology Presents Data on Two Lead Drug Candidates at ASCO 2018 Annual MeetingJune 4th, 2018
Defactinib Combined with Pembrolizumab and Gemcitabine in Patients with Advanced CancerApril 18th, 2016